Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 13Colorectal Neoplasms 9Neoplasm Metastasis 8Peritoneal Neoplasms 6Pancreatic Neoplasms 6Non-Muscle Invasive Bladder Neoplasms 6Appendiceal Neoplasms 6Stomach Neoplasms 5Carcinoma, Hepatocellular 5Anus Neoplasms 5Sarcoma 4Rectal Neoplasms 4Colonic Neoplasms 4Liver Neoplasms 3Carcinoma, Transitional Cell 3Pseudomyxoma Peritonei 2Mesothelioma, Malignant 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Anal Canal Carcinoma 2Urothelial Carcinoma of the Bladder 1Urologic Neoplasms 1Urologic Diseases 1Urinary Bladder Diseases 1Urethral Neoplasms 1Ureteral Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Pleural Neoplasms 1Pancoast Syndrome 1

Interventions

palbociclib 1Urinary Diversion 1Radiosurgery 1Mitomycin 1Immune Checkpoint Inhibitors 1Gels 1Cystectomy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Urologic Diseases × Mitomycin × Clear all
NCT02307487 2017-06-16

Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients

UroGen Pharma Ltd.

Phase 2 Completed
14 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Neoplasms, Urologic Diseases, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡